Related Experiment Video
Updated: Jul 13, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Development of therapeutics for AIDS: structure-based molecular targeting
1Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892, USA. maedak@mail.nih.gov
Tuberculosis (Edinburgh, Scotland)
|July 13, 2007
Summary
New anti-HIV-1 therapies show promise for managing infections. This review focuses on challenges and opportunities with CCR5 inhibitors and protease inhibitors for patients on highly active antiretroviral therapy.
Area of Science:
- Virology
- Pharmacology
- Immunology
Background:
- Novel therapeutics targeting HIV-1 replication are advancing treatment.
- Highly active antiretroviral therapy (HAART) improves HIV-1 management.
- Challenges exist in optimizing newer HIV-1 therapeutics.
Purpose of the Study:
- Discuss challenges in maximizing benefits of novel HIV-1 therapeutics.
- Highlight CCR5 as a therapeutic target for HIV-1 infection.
- Explore advancements in CCR5 inhibitor development and protease inhibitors.
Main Methods:
- Review of clinical trials for novel anti-HIV agents.
- Analysis of CCR5 inhibitor-CCR5 interactions.
- Discussion of therapeutic strategies for HIV-1 management.
Main Results:
- CCR5 inhibitors represent a promising new therapeutic target.
- Structural and molecular analysis offers insights into CCR5 inhibitor efficacy.
- Newer protease inhibitors show potential in HIV-1 treatment.
Conclusions:
- Optimizing HAART requires addressing challenges with novel therapeutics.
- CCR5 inhibitors and protease inhibitors are key areas for future HIV-1 research.
- Advancements in understanding molecular interactions can improve HIV-1 treatment outcomes.
Related Concept Videos
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...